[Selectivity of the reverse transcriptase inhibitors toward types 1 and 2 of human immunodeficiency virus (HIV)].
Two novel series of acyclonucleosides active as nonnucleoside reverse transcriptase inhibitors (NNRTI) against the human immunodeficiency virus (HIV) have been synthesized. Structural modifications, inverting the selectivity of classical NNRTI, considerably more active against HIV-1 than HIV-2, are reported. In these series, an increase in anti-HIV-2 activity is correlated with an increase of the cytotoxicity of these new molecules.
Tronchet
J M J
JM
Laboratoires CPOP, Section de Pharmacie, Faculté des Sciences, Université de Genève Sciences 2 CH-1211 Genève 4, Switzerland..
Apparu-Turquois
C
C
Laroze
N
N
Seman
M
M
D002478:Cells, Cultured; D015497:HIV-1 / Q000187:drug effects*; D015498:HIV-2 / Q000187:drug effects*; D006801:Humans; D009705:Nucleosides / Q000138:chemical synthesis / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D009705:Nucleosides; D018894:Reverse Transcriptase Inhibitors